Network News

State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026 FRANKLIN LAKES, N.J., Jan. 15, 2026 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal […]

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease NORWICH, UK & CHICAGO, US, January 6 2026 – Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an exclusive […]

Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Paris, December 23, 2025 – The European Commission has approved Wayrilz (rilzabrutinib), a novel, oral, reversible, Bruton’s tyrosine kinase (BTK) inhibitor, as a new treatment for immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. This follows the positive opinion by […]

Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025. Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (Dynavax), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and differentiated shingles vaccine […]

Heidelberg University Hospital (UKHD) is the first academic institution in Germany to receive a hospital exemption permit from the Paul Ehrlich Institute (PEI) for the manufacture and use of a novel cell product for the treatment of blood cancer. The drug “Heidagen-lecleucel” consists of modified, patient-specific immune cells known as chimeric antigen receptor (CAR) T […]

Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Paris, December 17, 2025. The European Medicines Agency (EMA) has granted orphan designation to efdoralprin alfa (SAR447537, formerly known as INBRX-101), an investigational recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, for the potential treatment of alpha-1 antitrypsin deficiency (AATD) related […]

It’s now official: the alliance between the two university hospitals in Heidelberg and Mannheim can start as planned on January 1 and begin its work. Press release from the Baden-Württemberg Ministry of Science, Research, and the Arts. Full Text in German below. Verträge zum Klinikverbund Heidelberg-Mannheim unterzeichnet Nun ist es offiziell: Der Verbund zwischen den […]

In March 2026, Kevin Jahnke will establish a research group on ‘Biomembrane Engineering’ at the new Heilbronn site of the Max Planck Institute for Medical Research. Its focus will be on engineering synthetic lipid nano- and microstructures, with the aim of investigating the biophysics of both cells and lipid vesicles.  Connecting biophysical insights with biotechnological […]

The Christiane Herzog Foundation has honored the Cystic Fibrosis Center at the Center for Pediatric and Adolescent Medicine and the Cystic Fibrosis Outpatient Clinic at the Thorax Clinic as the “Christiane Herzog Center.” With this award, the foundation recognizes the exceptional commitment and high level of expertise in the care of patients with cystic fibrosis […]